Cite

HARVARD Citation

    Keam, B. et al. (n.d.). 288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Journal for immunotherapy of cancer. p. A315. [Online]. 
  
Back to record